311 results about "Signal pathway" patented technology

The invention discloses a novel substituted heterocyclic compound with GSPTs / CK1a double-target degradation activity, and particularly discloses a compound which has the GSPTs / CK1a double-target degradation activity and is shown in a formula (I) or pharmaceutically acceptable salt, solvate, hydrate, isotope substitute or isomer of the compound. The compound can be used for preventing or treating diseases related to GSPTs / MYC / CK1a / WNT targets or signal pathways.

The invention discloses application of a stem cell exosome in treating depression-like behaviors caused by high-altitude hypoxia, and belongs to the technical field of biomedicine. The stem cell exosome is an exosome derived from human umbilical cord mesenchymal stem cells, and is used for drugs for preventing and / or treating depression-like behaviors caused by high-altitude hypoxia. The exosome can effectively improve depression-like core behavior symptoms caused by high-altitude hypoxia by regulating a brain-intestinal axis; the method starts from remodeling intestinal flora so as to influence the intracerebral metabolite spectrum, and finally plays a role in neuroprotection by regulating and controlling a 5-HT6 / cAMP-PKA key signal channel. In addition, the combination of the hUC-MSC-exo and probiotics shows synergistic interaction potential, and a potential treatment strategy which is novel in mechanism, remarkable in effect and high in safety is provided for the field.

The invention discloses a novel substituted heterocyclic compound with GSPTs / CK1a double-target degradation activity, and particularly discloses a compound which has the GSPTs / CK1a double-target degradation activity and is shown in a formula (I) or pharmaceutically acceptable salt, solvate, hydrate, isotope substitute or isomer of the compound. The compound can be used for preventing or treating diseases related to GSPTs / MYC / CK1a / WNT targets or signal pathways.

Systems, methods, and apparatuses disclosed herein can enable a computing system to connect to a network. These systems, methods, and apparatuses can connect the computing system to the network through multiple network connections. These multiple network connections represent distinct, physically separate signal pathways to improve security. This physical separation, or isolation, from one another creates distinct boundaries between these multiple network connections, for example, to minimize shared resources these systems, methods, and apparatuses. These distinct boundaries can reduce the vulnerability of these systems, methods, and apparatuses to, for example, attacks that exploit shared sources among these systems, methods, and apparatuses, data leakage within these systems, methods, and apparatuses, and / or unauthorized access to these systems, methods, and apparatuses. Moreover, these distinct boundaries can additionally enhance security by improving fault isolation, enforcing access control, and / or supporting secure communication protocols, among others, within these systems, methods, and apparatuses.

In one embodiment, an apparatus performs receiving, via two different signal pathways, at least two different signals that are associated with different radio wave characteristics; changing the frequency of signal(s) to provide intermediate signal(s) with each having different frequencies; multiplexing the intermediate signals to allow signals to be transmitted together via a single wired connection; receiving a multiplexed signal via the single wired connection, the multiplexed signal including intermediate further signals having different frequencies, the intermediate further signals also being associated with differing radio wave characteristics; and separating the intermediate further signals into separate signals; changing the frequency of the further signals to provide further signals at a transmission frequency; and transmitting the further signals via the two signal pathways.

The invention discloses a culture method for improving proliferation and differentiation capacity of NK (Natural Killer) cells based on angelica sinensis-astragalus membranaceus exosomes, which comprises the following steps: firstly extracting exosomes in angelica sinensis and astragalus membranaceus, then adding the exosomes into an NK cell culture system according to a specific concentration, and regulating and controlling an NK cell signal channel by virtue of active ingredients carried by the exosomes so as to improve the proliferation and differentiation capacity of the NK cells. Therefore, the proliferation rate and differentiation maturity of the NK cells are remarkably improved. Experimental results show that compared with a traditional culture method, the proliferation multiple of the NK cells cultured through the method is increased by 28.99%-33.69%, the proportion of differentiated mature cells is increased by 15.91%-28.30%, and the cell killing activity is not remarkably reduced. The method can be widely applied to the field of immune cell treatment, provides a high-quality NK cell source for clinic, effectively solves the problems of slow cell proliferation rate, low differentiation maturity, easy activity reduction after large-scale culture and the like in traditional NK cell in-vitro culture, and has important clinical application value and industrialization prospect.

The invention discloses an application of an AMPK (adenosine monophosphate kinase) activator or a PPAR (peroxisome proliferator activated receptor) gamma inhibitor in preparation of a medicine for preventing or treating diabetic osteoporosis. The invention discloses a key effect of a brand new signal channel, namely an AMPK-PPAR gamma-ERS axis, in osteogenic differentiation disorder of diabetes mellitus, and provides a method for preventing and treating diabetic osteoporosis by regulating and controlling the signal axis by taking metformin as a core. The invention provides new guidance for research and development of medicines for treating osteoporosis, and has potential clinical application and mechanism research values.

The invention discloses application of miR-101-3p in preparation of a medicine for treating myocardial fibrosis, and relates to the technical field of medicines. According to the invention, the influence of the miR-101-3p / RAC1 / PAK1 pathway on endothelial cells EndMT is verified by adopting human umbilical vein endothelial cells and utilizing molecular and cell biology means; and constructing an HFrMF mouse model, and verifying the feasibility of intervening the signal channel to alleviate MF. And a thought is provided for clarifying the pathological mechanism of heart failure and exploring a new treatment target.

The application of phlorizin in the medicine for treating and / or preventing lupus nephritis, the molecular formula of phlorizin is C 21 H 24 O 10 , the application promotes the differentiation of regulatory T cells (Treg) by applying phlorizin to up-regulate the PI3K / Akt signal pathway, thereby reducing the symptoms of lupus nephritis, and provides an effective treatment method with less side effects. In the application, the traditional Chinese medicine monomer phlorizin can effectively promote the differentiation of Treg cells, and compared with compound traditional Chinese medicine, the use of single component has more advantages in drug efficacy control and efficacy evaluation. In addition, phlorizin is widely sourced, low in cost and non-toxic, and is very suitable for long-term treatment of lupus nephritis.

The invention discloses an application of isoquercitrin in preparation of a medicine for improving insulin resistance and diabetes-related liver diseases, and belongs to the technical field of medicines. According to the application, a high-glucose and high-fat diet and streptozotocin combined method is adopted to successfully construct a type 2 diabetes mouse model; experiments find that the isoquercitrin can effectively relieve the symptoms of weight loss and water intake increase of T2DM mice, significantly reduce the fasting blood-glucose level and improve abnormal glucose tolerance; the isoquercitrin can reduce the liver index of a T2DM mouse, relieve fatty degeneration of the liver and repair a liver cell structure; by activating a PI3K / AKT signal channel, the isoquercitrin up-regulates the expression levels of PI3K, p-AKT, p-GSK3 and GLUT4 and down-regulates the expressions of GSK3 and PEPCK at the same time, so that the insulin resistance of T2DM mice is effectively improved, the fatty degeneration of the liver is improved, and the isoquercitrin has a protection or repair effect on liver injury.

The invention belongs to the technical field of semiconductor memory packaging, and particularly relates to a memory chip based on two-dimensional material and CMOS circuit 2.5 D integration and a preparation method thereof. According to the chip, a 2.5 D packaging structure is adopted, two-dimensional material ultra-flash memory device core particles and peripheral control circuit core particles prepared by adopting a standard CMOS technology are integrated on an intermediate layer, reliable electric connection is achieved through a metal bump-solder ball interconnection structure, a low-temperature flip-chip technology is adopted in the packaging process, and therefore the reliability of the chip is improved. The design of a multi-layer metal bump laminated structure is matched, and the heat sensitivity and interconnection reliability of the two-dimensional material are considered; and the intermediate layer is further connected with a PCB test board below the intermediate layer to construct signal channels among the core particles and outside the chip. According to the structure, the ultrafast programming / erasing characteristic of the two-dimensional material flash memory and the logic function advantage of the CMOS circuit are fully combined, and a feasible path and technical support are provided for engineering and system-level application of a two-dimensional material ultrafast memory device.

This invention relates to the field of cosmetic compositions, and more specifically to a synergistic anti-aging composition involving energy metabolism and autophagy, its preparation method, and its application. The composition comprises sea buckthorn fruit extract, trehalose, and a cosmetically acceptable polyol carrier. This invention pioneers a betaine-trehalose-NADES extraction system, achieving low-temperature, high-efficiency extraction while preserving the heat-sensitive active ingredients of sea buckthorn. Trehalose possesses both extraction and autophagy activation effects. A selective separation strategy achieves a balance between efficacy, compliance, and process simplicity. The green, circular process reduces costs and is environmentally friendly. Through the synergistic effect of sea buckthorn fruit extract and trehalose, the composition enhances mitochondrial membrane potential, increases ATP production, inhibits excessive activation of the mTOR pathway, and promotes LC3-II conversion, thus synergistically combating skin aging from multiple targets including cellular energy metabolism, signaling pathways, and autophagy.

The invention relates to the technical field of molecular biology and the technical field of gene editing, in particular to pegRNA of a specific target EGFR gene tyrosine 1068 site, a pilot editing system and application. The pegRNA comprises sgRNA (small guide RNA), sgRNA scaffold, an RT (reverse transcription) template and PBS (phosphate buffer solution); wherein the sequence of the pegRNA is as shown in SEQ ID NO. 1; the sequence of the sgRNA is as shown in SEQ ID NO. 2; the sequence of the sgRNA scaffold is as shown in SEQ ID NO. 3; the sequence of the RT template is as shown in SEQ ID NO. 4; the sequence of the PBS is as shown in SEQ ID NO. 5. The tyrosine 1068 site of the EGFR gene is mutated into phenylalanine, so that phosphorylation of the site is blocked, and a protein structure is maintained. The tyrosine 1068 site point mutant with the EGFR gene can be applied to research on preparation of drugs for treating cancers, research on drug resistance and research on screening of compounds of targeted EGFR signal channels.

The invention provides application of taurochenodeoxycholic acid in preparation of a medicine for preventing and / or treating Fuchs corneal endothelial dystrophy, and particularly belongs to the technical field of medicine preparation. The invention provides an application of taurochenodeoxycholic acid in preparation of a medicine for preventing and / or treating Fuchs corneal endothelial dystrophy. Test results show that taurochenodeoxycholic acid can realize prevention and / or treatment of corneal endothelial cell injury caused by UVA; the number reduction, activity reduction, oxidative stress, ROS level rise and mitochondrial membrane potential drop of corneal endothelial cells caused by UVA are relieved; mitochondrial biological energy deficiency caused by UVA is relieved; and the prevention and / or treatment of the Fuchs corneal endothelial dystrophy are / is realized by activating a Ca < 2 + > signal channel.

The invention discloses a method for cultivating low-potassium-tolerant rice. The rice OsSPL19 gene is directionally knocked out by using a CRISPER / Cas9 technology, and it is found that a transgenic plant with the OsSPL19 gene knocked out is sensitive to low potassium, the plant is short and small under low potassium treatment, the root is shortened, the potassium ion content of the root and the overground part is obviously reduced, and the potassium ion absorption capacity of the root is obviously reduced. Overexpression of the OsSPL19 gene in rice shows that a plant overexpressed by the OsSPL19 gene is tolerant to low potassium and grows well under a low-potassium condition, the potassium ion content of plant roots and overground parts is obviously increased, and the potassium ion absorption capacity of the roots is obviously enhanced. The result shows that the OsSPL19 gene participates in a rice low-potassium-resistant signal pathway and is a rice low-potassium-resistant gene. According to the invention, guarantee can be provided for improving the low-potassium resistance of the rice and cultivating low-potassium-resistant rice varieties.

The application discloses application of PGD2 in promoting rumen development of young ruminants, and application of PGD2 in young ruminants promotes proliferation and differentiation of rumen wall cells, and further promotes rumen development and improves the digestive and absorptive capacity of the rumen. 2+ It is found that PGD2 can promote rumen development by activating Ca signal pathways, promoting expression of CAMK2A protein, promoting cell cycle progression, promoting rumen development, and ensuring animal health. Therefore, PGD2 can be used for preparing a medicine for promoting rumen development of young ruminants.

The invention belongs to the field of molecular biology, particularly relates to the field of tumor treatment, and particularly relates to application of a TRK inhibitor LYS-8 in preparation of a medicine for treating malignant tumors, particularly pancreatic cancer. LYS-8 is a small molecule TRK inhibitor with a novel structure, and research finds that LYS-8 can significantly inhibit TRK kinase activity and down-regulate downstream PI3K-AKT and other signal channels. Experimental results show that the inhibition effect of LYS-8 in pancreatic cancer cells is obviously superior to that of colorectal cancer cells, and the IC50 value of LYS-8 is lower; in an animal model, the tumor inhibition rate of LYS-8 on pancreatic cancer reaches about 70%, and the inhibition rate on colorectal cancer is about 56%, which is obviously superior to that of a colorectal cancer model. The invention reveals that LYS-8 has an unexpected curative effect advantage on pancreatic cancer, and a new drug choice is provided for targeted therapy of pancreatic cancer.

The invention discloses an application of indole-3-pyruvic acid in preparation of an NF-kappa B signal channel activator. The research on the influence of the indole-3-pyruvic acid on NF-kappa B signal channels in breast cancer cells and killer T cells (CD8 + T cells, Tc) proves that the indole-3-pyruvic acid can activate the NF-kappa B signal channels in the breast cancer cells and the CD8 + T cells, so that the indole-3-pyruvic acid can be used for preparing the medicine for improving the tumor immunosuppressive microenvironment.

The application belongs to the technical field of molecular biology and medicine, and discloses a methylation marker for detecting the benignity and malignancy of thyroid nodules and an application. 780 new methylation sites are identified, 273 tumor occurrence and development related genes are associated, and the Fc gamma R-mediated phagocytosis signal pathway is involved. The methylation marker for detecting the benignity and malignancy of thyroid nodules comprises multiple genes and multiple methylation sites. The methylation level of multiple genes and multiple sites is detected, the problem of low and unstable methylation signal of single gene or single site is overcome, and thus the sensitivity and specificity of detection are improved.

The embodiment of the invention discloses application of ALDH3A2 as a target spot in preparation of a medicine for treating gastric cancer. The research clarifies a new effect and a potential mechanism of ALDH3A2 in the aspect of inhibiting gastric cancer progression. Specifically, the ALDH3A2 can be used for down-regulating the expression of SLC47A1, so that the nuclear transfer of NRF2 is prevented, and the activation of UPRmt is inhibited. The damage can aggravate mitochondrial dysfunction, and finally, gastric cancer cell ferroptosis is promoted in a glutathione peroxidase 4 (GPX4) dependent mode. In addition, ferroptosis induced by ALDH3A2 can also promote polarization of macrophages to M1 type, and the progress of gastric cancer cells is inhibited through an IL-1beta signal channel. In conclusion, the effects jointly inhibit proliferation, migration and invasion of gastric cancer cells, and finally inhibition of growth and metastasis of gastric cancer is achieved.

The application relates to the application of lycorine hydrochloride in the preparation of a medicine for inhibiting the proliferation of a neointimal in a blood vessel. Lycorine hydrochloride has the effect of inhibiting the proliferation of a neointimal in a blood vessel, and the effect is mainly realized by inhibiting the proliferation and migration of vascular smooth muscle cells. In the body, the results show that lycorine hydrochloride can significantly inhibit the intimal proliferation caused by left common carotid artery ligation, and in vitro experiments prove that lycorine hydrochloride can intervene in the proliferation, migration and phenotype transformation of VSMCs induced by PDGF-BB. Lycorine hydrochloride inhibits the proliferation, migration and phenotype transformation of VSMCs induced by PDGF-BB, and the proliferation of a neointimal in a blood vessel through a MAPKs signal path. The application provides data for preparing lycorine hydrochloride into a medicine for inhibiting the proliferation of a neointimal in a blood vessel, and is expected to be applied to the prevention and treatment of complications after percutaneous coronary intervention, such as restenosis or in-stent thrombosis, and can become a potential medicine for intervening in restenosis.

The invention discloses application of baclofen in preparation of a medicine for treating glioma, and belongs to the technical field of biological medicine. Through systematic in-vitro and in-vivo experiments, it is proved for the first time that baclofen (especially R-configuration) has a remarkable anti-tumor effect on glioma including temozolomide (TMZ) drug resistance. The invention not only provides a brand-new clinical strategy for treating TMZ drug-resistant glioma, but also shows important value in the field of scientific research: baclofen can be used as a valuable tool compound and is used for exploring a new function of a GABAB receptor signal channel in glioma progress and drug resistance; meanwhile, a key tool is provided for constructing a stable TMZ drug-resistant model, the high-throughput drug screening and evaluation efficiency can be remarkably improved, and the TMZ drug-resistant monoclonal antibody can serve as a positive control drug to accelerate the conversion process from basic research of glioma to clinical application and has wide scientific research application prospects and conversion potential.

The application is suitable for the field of biological medicine technology, and provides a siRNA-PSMA conjugate targeting a LEPR gene, a preparation method and application thereof. The siRNA-PSMA conjugate realizes specific targeted delivery of CRPC cells through a PSMA inhibitor target head, effectively reduces off-target toxicity, combines with a high-interference-efficiency M3 modified LEPR siRNA screened, can efficiently silence LEPR gene expression, block a leptin-LEPR signal pathway, and then inhibit CRPC cell proliferation, invasion and drug resistance related biological functions; the preparation process is stable and controllable, the purity of the finished product after purification can reach more than 95%, meets the quality requirements of drug development, and the activity verification method has strong specificity and reliable results, fills the blank of CRPC targeted therapy drugs in the prior art, provides a new precise targeting strategy for CRPC treatment, and has important clinical application value and broad conversion prospect.

The application discloses an application of a TLR4 / NF-kappa B signal path inhibitor in preparation of a medicine for improving hematopoietic function of anemic inflammatory, relates to the technical field of biology and medicine, and discloses an application of the TLR4 / NF-kappa B signal path inhibitor in preparation of a medicine for improving hematopoietic function of anemic inflammatory, wherein the TLR4 / NF-kappa B signal path inhibitor is Danggui Buxue Decoction; the Danggui Buxue Decoction is composed of Astragalus and Angelica with a mass ratio of 5:1; the TLR4 / NF-kappa B signal path inhibitor is used for down-regulating expression of TLR4 protein and NF-kappa B protein in liver tissue; the improvement of hematopoietic function of anemic inflammatory includes increasing peripheral blood red blood cell count, white blood cell count, platelet count and hemoglobin level; the Danggui Buxue Decoction is used as the TLR4 / NF-kappa B inhibitor to improve anemic inflammatory, can down-regulate TLR4 / NF-kappa B expression, improve blood cells and hemoglobin, improve bone marrow pathology, reduce inflammatory factors and hepcidin, increase iron content, and provide a corresponding curative effect evaluation method, and provides a new choice for anemic inflammatory treatment.

A pyrrolopyrimidine or pyrrolopyridine derivative and its medical use. Specifically, the compound has the structure shown in formula I, has good inhibitory effect on focal adhesion kinase (FAK), and can inhibit its related signal pathways, and can be prepared for treating or preventing diseases related to cancer, pulmonary arterial hypertension, pathological angiogenesis, etc., and can be particularly used for treating diseases caused by excessive or abnormal cell proliferation, such as tumors or cancers.

The invention discloses a composite medicine coating for treating pulmonary arterial hypertension, and belongs to the technical field of medical instruments. The coating is composed of an inert protective layer and a composite drug coating, the inert protective layer is a polyamino acid polymer, responds to pH change and is rapidly disintegrated only in the pH environment of a target site, and the loss of the composite drug coating in the delivery process is reduced; the composite drug coating is a composite component containing two or more gene regulatory factors and / or drugs, achieves a synergistic effect through a signal path, cells and a gene level, more efficiently regulates pulmonary artery endothelial cell dysfunction and smooth muscle cell injury, and has precise targeting and irreplaceability.

The invention discloses a novel ALS disease model and application thereof in screening ALS treatment drugs, and belongs to the technical field of disease models and drug screening. According to the method, induced pluripotent stem cells derived from a sporadic ALS patient are directionally induced into spinal cord organs, the spinal cord organs and immune cells derived from the same donor form a co-culture system, the co-culture system is infected with viruses, and the ALS disease model is successfully constructed. According to the method, ALS diseases are simulated on the three-dimensional level, ALS disease models of all stages (including the initial stage of the diseases) are obtained, and the pathological features of all the disease stages of ALS (especially 90% or above of sporadic ALS) can be accurately reflected; the problem that key disease-promoting factors in the early stage of the disease cannot be obtained due to complete disorder of downstream signal channels in the end stage of the disease after definite diagnosis caused by slow definite diagnosis of hidden disease onset of the ALS is solved.

Provided is an RNA editing system activating a Wnt signaling pathway, relating to the field of gene editing. Provided is an RNA editing element, comprising an Axin1-targeting RNA fragment and an Axin2-targeting RNA fragment. A gRNA that targets both Axin1 and Axin2 is constructed, which, compared with gRNAs targeting Axin1 or Axin2 alone, can significantly up-regulate Wnt activity. An AAV6 vector is screened from three AAV vectors of different serotypes, and exhibits relatively high expression intensity and efficiency and high infection efficiency with respect to airway epithelial cells and alveolar epithelial cells while exhibiting very low infection efficiency with respect to immune cells and endothelial cells. The AAV vector is assembled with a Cre-LoxP recombinase system to together infect a host cell, thereby facilitating the measurement of Cas13d knockdown efficiency by means of fluorescent labeling.

The invention discloses asterias amurensis glucan as well as a preparation method and application thereof, and belongs to the technical field of biological medicine, the asterias amurensis glucan is obtained by combining an enzymolysis method with anion exchange column chromatography and gel column chromatography purification, the main chain structure of the asterias amurensis glucan is 1, 4-linked alpha-D-glucose, and the main chain structure of the asterias amurensis glucan is 1, 4-linked alpha-D-glucose. A terminal alpha-D-glucose branch chain is arranged at the O-6 position of a main chain, and meanwhile, a small amount of mannose and galactose are contained. Moreover, it is proved for the first time that the asterias amurensis glucan can serve as an intestinal barrier protective agent, and oxidative damage, caused by H2O2, of intestinal epithelial cells is improved by up-regulating an Nrf2 signal channel and tight junction protein. Therefore, the asterias amurensis glucan prepared by the invention has a huge potential of being developed into medicines and health-care products for protecting intestinal tracts.